INTRODUCTION
============

Glaucoma is characterized by irreversible damage to the optic nerve, which can cause blindness, and is the leading cause of irreversible blindness worldwide. Globally, 64.3 million people were estimated to have glaucoma in 2013, with the number expected to increase to 111.8 million in 2040 \[[@B1]\]. Although irreversible, its progression can be delayed by treatment; therefore, identifying risk factors associated with the disease to promote earlier detection is important.

Many risk factors for glaucoma development have been recognized including increased intraocular pressure (IOP) \[[@B2]\], family history of glaucoma \[[@B3]\], age \[[@B4]\], and African ancestry \[[@B5]\]. In addition, hemodynamic factors have been identified to play an important role in the pathogenesis of primary open-angle glaucoma (POAG); thus, metabolic health status and obesity may affect POAG development \[[@B6],[@B7]\]. However, metabolic health status and obesity have been shown to have conflicting relationships with glaucoma \[[@B6][@B8][@B9][@B10][@B11][@B12][@B13][@B14]\]. This inconsistency could be attributed to differences in the characteristics of the study population, dissimilar definitions or categories of diseases, or variation in follow-up periods. It may also be due to interactions between metabolic health and obesity. It has been suggested that, despite similarities in obesity level, which is most frequently measured by body mass index (BMI), individuals show different clinical outcomes depending on metabolic statuses \[[@B15][@B16]\]. Individuals who are obese but metabolically healthy show lower degrees of insulin resistance, visceral adiposity, and cardiovascular risk. Conversely, individuals who are nonobese but metabolically unhealthy show higher degrees of insulin resistance, visceral adiposity, blood pressure (BP), oxidative stress, and cardiovascular mortality \[[@B16][@B17][@B18][@B19]\].

To the best of our knowledge, the risk of POAG development has not been previously compared in the context of combinations of metabolic status and obesity. Therefore, in this study, we assessed the effects of metabolic status and obesity, both presence and severity, on development of POAG using a nationwide longitudinal sample of individuals enrolled from throughout South Korea. Furthermore, we sought to understand how different combinations of metabolic status and obesity affected the likelihood of developing POAG after adjusting for potentially confounding factors.

METHODS
=======

Database
--------

The Korean National Health Insurance System (KNHIS) requires that all South Koreans enroll in the system and contains comprehensive health-related information for all nationals. With this system, medical providers receive 30% of total medical expenses from patients themselves and the other 70% from the KNHIS, for which they must submit claims \[[@B20]\]. In addition, the KNHIS offers free general health checkups to all insured Koreans and their dependents over the age of 40 years, at least biennially. The KNHIS contains data regarding personal information about the patient (an unidentifiable code representing each individual as well as age, sex, socioeconomic variables, area of residency, and household income level), medical treatment based on medical claims made by medical providers (diagnostic codes, treatment procedures, prescription drugs, information about the hospital, total medical costs), and the results of general health examination. A customized database of 1,025,340 subjects (2.2%) was compiled from the entire Korean population in 2002 (46,605,433 subjects) by stratified random sampling to represent the total population, and the subjects were tracked until 2013.

The KNHIS national sample cohort 2002 to 2013 (KNHIS-NSC 2002 to 2013) project was approved by the Institutional Review Board of the KNHIS. This study followed the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul St. Mary\'s Hospital (KC15EISI0294). Written informed consent by the patients was waived due to a retrospective nature of our study.

Participants
------------

From the KNHIS-NSC 2002 to 2013 project, we included subjects who had undergone a general health examination at least once between 2002 and 2008 (*n*=424,712). Subjects were identified as having POAG if they had at least two visits for POAG (International Classification of Diseases \[ICD\]-10 code H40.1) and received antiglaucoma medications during the study period. We excluded subjects aged younger than 40 years (*n*=136,834) and those who were diagnosed with POAG prior to enrollment (*n*=325) to exclude nonincident cases. Ultimately, the study included 287,553 subjects. If a subject underwent more than one health examination, the results from their first health examination were included in the analysis.

Measurements and demographic factors
------------------------------------

Health examinations were performed in hospitals that were certified by the KNHIS. Anthropometric measurements were performed with the subjects wearing light clothing. BMI was calculated as subject weight in kilograms divided by the square of subject height in meters. BP was measured in a seated position after an at least 5-minute rest. Blood samples for glucose serum and total cholesterol (TC) levels were collected following overnight fasting. Data on history of smoking (no, past, or current), alcohol consumption (no, less than two to three times/month, once or more/week), and exercise (no activity, less than four times/week, or five times or more/week) were obtained using a questionnaire. Subject medication history was gathered based on clinic and pharmacy ICD-10 codes, list of prescribed medications, and medical history obtained via a questionnaire. Subject socioeconomic status was dichotomized into lower 20% and upper 80% groups based on household income. Area of residency was categorized as either urban or rural.

Definitions of metabolically healthy obesity
--------------------------------------------

Metabolically healthy patients were defined as those who were free of metabolic syndrome components. If a subject had at least one of diabetes mellitus (DM), hypertension, and hypercholesterolemia, the participant was considered to be metabolically unhealthy. DM was defined based on ICD-10 codes (E11-E14) and prescription of antidiabetic medications or a fasting plasma glucose (FPG) ≥126 mg/dL. Hypertension was defined based on ICD-10 codes (I10, I11, I12, I13, and I15) and prescription of antihypertensive medications, a systolic BP (SBP) ≥140 mm Hg, or a diastolic BP (DBP) ≥90 mm Hg. Prehypertension was defined as a SBP from 120 to 139 mm Hg or a DBP from 80 to 89 mm Hg. Hypercholesterolemia was defined based on an ICD-10 code (E78) and prescription of cholesterol medications or TC ≥240 mg/dL. Obesity was defined as BMI ≥25 kg/m^2^.

Subjects were categorized into the following four groups based on metabolic status and obesity: metabolically healthy nonobese (MHNO), metabolically unhealthy nonobese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO).

Statistical analyses
--------------------

Student *t*-test was used to compare continuous variables, and chi-square test was used to compare categorical variables. The duration of follow-up (person-years) was calculated from the enrollment date (2002 to 2008) to the date of POAG diagnosis or to the end of follow-up (December 2013). Cox proportional hazards analysis was performed to estimate the overall hazard ratio (HR) and 95% confidence interval (CI) for the associations of DM, hypertension, hypercholesterolemia, and BMI with POAG development. To identify the graded risk of POAG development by level of metabolic syndrome component, DM, hypertension, hypercholesterolemia, and obesity were each stratified into subgroups based on levels of FPG (FPG \<100, 100≤ FPG \<126, 126 mg/dL ≤FPG, or on medication); SBP or DBP (SBP \<120 or DBP \<80, 120≤ SBP \<140 or 80≤ DBP \<90, SBP ≥140 or DBP ≥90 mmHg, or on medication); TC (TC \<200, 200≤ TC \<240, 240 mg/dL ≤ TC, or on medication); and BMI (\<18.5, 18.5 to 22.9, 23 to 24.9, 25 to 29.9, and ≥30 kg/m^2^), respectively.

In addition, we calculated the HR of incident POAG according to number of metabolic syndrome components. We also calculated the HR of each metabolic syndrome component and obesity level for new-onset POAG, stratified by sex and age (\<64 years vs. ≥65 years). The Kaplan-Meier curve was used to calculate the overall disease-free rate, while the log-rank test was performed to investigate the differences in the effect of metabolic state and obesity on POAG development. Furthermore, we examined the association between groups stratified according to metabolic status and obesity and POAG incidence. Multivariable HRs were calculated after adjusting for age, sex, smoking, exercise, and income. A *P* value less than 0.05 was considered significant. All statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

Of the 287,553 participants who were included in the present analysis, 4,970 (1.73%) developed POAG. Baseline characteristics of participants with and without incident POAG are shown in [Table 1](#T1){ref-type="table"}. Participants who developed POAG were more likely to be older than 65 years and male. These individuals additionally showed higher BMI, SBP, DBP, serum glucose, and TC levels than did those without POAG.

Association with open-angle glaucoma: components of metabolic syndrome and BMI
------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows the HR for POAG according to DM, hypertension, and hypercholesterolemia parameters as well as obesity levels and number of metabolic syndrome components. People with higher FPG level had a higher risk of developing POAG (\[HR, 1.21; 95% CI, 1.13 to 1.29\] and \[HR, 1.54; 95% CI, 1.36 to 1.74\] for 100≤ FPG \<126 and FPG ≥126 mg/dL, respectively). People with prior diagnosis of DM who were under medication also had increased risk of developing POAG (HR, 3.26; 95% CI, 3.01 to 3.53). Separately, people with higher SBP or DBP were more likely to develop POAG (\[HR, 1.23; 95% CI, 1.13 to 1.34\] and \[HR, 1.68; 95% CI, 1.53 to 1.84\] for 120≤ SBP \<140 or 80≤ DBP \<90 and SBP ≥140 or DBP ≥90 mm Hg, respectively). Those with prior diagnosis of hypertension who are on medication were also more likely to develop POAG (HR, 2.83; 95% CI, 2.61 to 3.08). People with higher cholesterol levels showed increased risk of developing POAG (\[HR, 1.09; 95% CI, 1.02 to 1.16\] and \[HR, 1.30; 95% CI, 1.19 to 1.41\] for 200≤ TC \<240 and 240 mg/dL ≤ TC, respectively). People with prior diagnosis of hypercholesterolemia on medication showed a higher risk of developing POAG (HR, 2.14; 95% CI, 1.95 to 2.35), and people with a greater number of metabolic syndrome components were more likely to develop POAG (\[HR, 1.77; 95% CI, 1.66 to 1.89\], \[HR, 2.74; 95% CI, 2.54 to 2.96\], and \[HR, 4.17; 95% CI, 3.68 to 4.72\] for one, two, and three risk factors, respectively).

Regarding obesity, people with BMI of 30 kg/m^2^ or greater were more likely to develop POAG than those with BMI between 18.5 and 22.9 kg/m^2^, in a statistically significant manner (HR, 1.35; 95% CI, 1.16 to 1.56).

Furthermore, after stratifying by age, those younger than 65 years showed a relatively higher risk of developing POAG at higher levels of FPG, BP, cholesterol, and BMI and with greater number of metabolic syndrome components ([Table 3](#T3){ref-type="table"}). In comparison, those who were 65 years old or older showed relatively weaker relationships; those with prior diagnosis of DM, hypertension, or hypercholesterolemia under medication showed greater risk of developing POAG, but the levels of FPG, BP, cholesterol, and BMI did not lead to a statistically significant difference regarding the hazard of developing POAG. Separately, those aged 65 years or older with a greater number of metabolic syndrome components showed a greater risk of incident POAG. Also, in terms of absolute risk increment, the incidence rates of developing POAG at higher levels of FPG, BP, cholesterol, and BMI were higher in those younger than 65 years of age compared with those 65 years of age or older.

Moreover, when stratified by sex, both men and women exhibited significantly higher risks of developing POAG at higher levels of FPG, BP, and cholesterol and with greater number of metabolic syndrome components, but the HR was higher in women than in men ([Table 4](#T4){ref-type="table"}). Regarding BMI, higher BMI level increased the hazard of developing POAG only in women (\[HR, 1.14; 95% CI, 1.03 to 1.27\], \[HR, 1.25; 95% CI, 1.13 to 1.38\], and \[HR, 1.61; 95% CI, 1.33 to 1.94\] for BMI of 23 to 24.9, 25 to 29.9, and ≥30 kg/m^2^, respectively).

Association with open-angle glaucoma: MHO individuals vs. MUNO individuals
--------------------------------------------------------------------------

[Table 5](#T5){ref-type="table"} shows HR values for developing POAG according to metabolic syndrome component and obesity status with and without adjustment for confounding factors.

Compared with MHNO subjects, MUO individuals had an increased hazard of developing POAG before and after adjusting for age, sex, and sociodemographic confounding factors (\[HR, 2.056; 95% CI, 1.903 to 2.220\] and \[adjusted HR, 1.574; 95% CI, 1.449 to 1.711\]). MUNO individuals also showed a higher risk of developing POAG before and after adjusting for confounders (\[HR, 2.191; 95% CI, 2.040 to 2.354\] and \[adjusted HR, 1.521; 95% CI, 1.405 to 1.645\]), while MHO patients showed no significant difference in hazard of developing POAG before and after adjusting for covariates (\[HR, 1.038; 95% CI, 0.931 to 1.157\] and \[adjusted HR, 1.019; 95% CI, 0.907 to 1.144\]).

[Fig. 1](#F1){ref-type="fig"} shows Kaplan-Meier survival analysis for development of POAG according to metabolic status and obesity.

DISCUSSION
==========

In this study, all components of metabolic syndrome including DM, hypertension, and hypercholesterolemia individually increased the risk of developing POAG. Also, higher level of FPG, BP, and TC each increased the risk of POAG incidence. Furthermore, a greater number of metabolic syndrome components and higher level of FPG, BP, or cholesterol independently increased this risk. These trends were similarly observed among both sexes and across age groups.

Moreover, regarding different combinations of metabolic status and obesity, we observed that metabolic status was more important than obesity, as individuals who were MUNO or MUO showed higher risk of developing POAG in comparison with those who were MHNO, whereas those who were MHO did not. This relationship was significant both before and after adjusting for age, sex, and sociodemographic confounding factors.

Other studies have reported the association between metabolic syndrome and POAG development with various results. Newman-Casey et al. \[[@B6]\] found that DM (HR, 1.35; 95% CI, 1.21 to 1.50) and hypertension (HR, 1.17; 95% CI, 1.13 to 1.22) individually increased the risk of developing open-angle glaucoma using medical claims data from throughout the United States. However, in their study, hyperlipidemia decreased the risk of open-angle glaucoma (HR, 0.95; 95% CI, 0.91 to 0.98). In another study by Imai et al. \[[@B8]\], high levels of FPG, BP, and triglycerides were each related with high IOP. Kim et al. \[[@B9]\] reported that hypertension and impaired glucose tolerance were related with increased risk of glaucoma. In a cross-sectional study performed using a nationwide database, the prevalence of glaucoma was statistically significantly higher in those with greater numbers of metabolic syndrome components \[[@B9]\]. In addition, in the same study, the prevalence values of hypertension, high FPG, and high triglycerides were higher in those with glaucoma than those without. Kim et al. \[[@B10]\] additionally reported a positive association between number of metabolic syndrome components and glaucoma.

There could be several possible reasons for increased risk of POAG development in patients with metabolic syndrome. First, metabolic syndrome may increase IOP. Participants with metabolic syndrome showed higher IOP than did those without, and those with greater number of metabolic syndrome components also had higher IOP \[[@B8][@B21][@B22]\]. It has been hypothesized that hypertension may increase IOP by promoting greater blood flow to the ciliary artery, which results in excessive aqueous humor production \[[@B23]\]. Also, DM may elevate IOP by increasing the osmotic gradient, which can draw more aqueous humor into the anterior chamber \[[@B21]\]. This can also cause fibronectin accumulation in the trabecular meshwork, interrupting the aqueous outflow facility \[[@B24]\].

However, metabolic syndrome is reported to be related with certain findings in even normal-tension glaucoma (NTG) \[[@B10]\]. In one study, metabolic syndrome was independently related with reduced retinal nerve fiber layer thickness, suggesting that metabolic syndrome may also be related with neurodegeneration in glaucoma \[[@B25]\]. The positive relationship between metabolic syndrome components and POAG in our investigation emphasized the possible relationship between metabolic syndrome and neurodegeneration in glaucoma, considering the greater prevalence of NTG in comparison with high-tension glaucoma in Koreans than in other ethnicities \[[@B26]\].

Kim et al. \[[@B10]\] reported in a cross-sectional study that hypertension and impaired glucose tolerance increased the risk of NTG, and a greater number of metabolic syndrome components was positively related with NTG. Hypertension may cause arteriolosclerotic damage, while DM also causes damage to small blood vessels, which can reduce blood flow to the optic nerve head and promote endothelial cell dysfunction; this affects vascular autoregulation, increasing vulnerability to glaucomatous neurodegeneration \[[@B27][@B28]\]. Hypercholesterolemia is an important risk factor for atherosclerosis \[[@B29]\] and may also reduce blood flow to the optic nerve head, resulting in ischemic damage to the retinal ganglion cells.

In our study, people with BMI of 30 kg/m^2^ or greater were more likely to develop POAG than were those with BMI between 18.5 and 22.9 kg/m^2^. In a subgroup analysis, this relationship was significant in those younger than 65 years of age and in women. Previous studies have noted that higher BMI was related with higher IOP, which is a major risk factor for POAG \[[@B30][@B31]\]. Cohen et al. \[[@B32]\] reported that obesity was an independent risk factor for elevated IOP. The Rotterdam Study separately reported that obesity was related with higher IOP \[[@B33]\]. The relationship between obesity and POAG, however, has not been established in a consistent manner. In a population-based study in the United States, Ko et al. \[[@B11]\] reported that BMI of 30 kg/m^2^ or greater was significantly associated with prevalence of glaucoma. Elsewhere, Zang and Wynder \[[@B14]\] found that high BMI was associated with glaucoma. However, more studies have contrarily reported that prevalence of open-angle glaucoma was lower in the obese population \[[@B9][@B12][@B13]\]. The Barbados Eye Study also reported that those with high BMI showed decreased odds of open-angle glaucoma \[[@B12]\]. Nangia et al. \[[@B13]\] reported that lower BMI was related with higher prevalence of glaucoma based on a population study in Central India. In addition, Gasser et al. \[[@B34]\] reported that obesity was not a risk factor for glaucoma. These variations in results may be caused by different sociodemographic characteristics of the study populations, different definitions used to define metabolic syndrome or POAG, and different factors used to adjust for confounding effects. The association between BMI and POAG remains unclear, and further research is warranted.

Furthermore, in subgroup analyses, the relative risk effects and the effect of metabolic syndrome components assessed by absolute incidence increments were greater in younger subjects. Similar results were found in the Blue Mountains Eye Study, in which the association between DM and POAG was significant in the younger age group but not in the older age group (≥70 years) \[[@B35]\]. The reason for this is unclear. Metabolic syndrome components may play a more important role in development of POAG in younger individuals. This may also be partly due to selection bias, indicating that younger subjects with metabolic syndrome components are more likely to visit an ophthalmologist than are those without \[[@B36]\].

We also compared the HR of developing POAG according to metabolic syndrome components and obesity status. Interestingly, those who were characterized as MUNO showed higher risk of developing POAG than those who were MHNO, but those who were MHO did not, indicating that metabolic status is more important than obesity. People who were MUNO were shown to exhibit impaired insulin sensitivity as well as higher BP, oxidative stress, abdominal adiposity, atherogenic lipid profile, risk of cardiovascular disease \[[@B37][@B38][@B39]\], and higher mortality compared with those who were MHO \[[@B17][@B40][@B41][@B42]\].

The strengths of this study are its large sample size representing nationwide data and the combination of medical claims data and health examination data. In addition, it is a prospective longitudinal cohort study that provides incidence and establishes the temporal sequence required for causal inference. Also, it provides graded associations between metabolic disease severity, obesity, and POAG.

When interpreting our data, the following should be taken into consideration. First, patients with POAG were identified based on ICD-10 codes; those who did not visit hospitals were not included in this study. In addition, no information about POAG severity or subtype was available, so we could not grade the associations between metabolic status, obesity, and POAG. Furthermore, other metabolic components such as waist circumference, high-density lipoprotein C, and triglyceride level could not be included in our analysis because they were not included in the health examination until 2009, when the National Health Insurance Service revised the health examination categories.

In conclusion, we found that metabolic health status significantly increased the risk of POAG in this prospective cohort from a nationwide database. This emphasizes the importance of glaucoma screening in patients with metabolic syndrome and obesity, including not only those who are MUO, but also those who are MUNO.

The National Health Insurance Claims Database was provided by the National Health Insurance Sharing Service (NHISS) of Korea.
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###### Comparison of baseline characteristics between subjects with and without glaucoma

![](dmj-44-414-i001)

  Characteristic                        Development of glaucoma                     
  ------------------------------------- ------------------------- ----------------- ---------
  Age ≥65 yr                            1,687 (33.94)             44,790 (15.85)    \<0.001
  Male sex                              2,603 (52.37)             138,576 (49.04)   \<0.001
  Height, cm                            160.4±9.1                 161.2±8.9         \<0.001
  Weight, kg                            62.3±10.6                 62.3±10.5         0.882
  BMI, kg/m^2^                          24.1±3.1                  23.9±3.1          \<0.001
  SBP, mm Hg                            130.4±18.3                126.1±17.8        \<0.001
  DBP, mm Hg                            80.3±11.5                 78.6±11.5         \<0.001
  Fasting plasma glucose, mg/dL         107.1±43.3                98.5±31.3         \<0.001
  Total cholesterol, mg/dL              202.3±39.5                198.5±38.2        \<0.001
  Smoking                                                                           \<0.001
   No                                   3,363 (74.82)             185,671 (72.18)   
   Past                                 216 (4.81)                11,817 (4.59)     
   Current                              916 (20.38)               59,761 (23.23)    
  Alcohol                                                                           \<0.001
   No                                   3,021 (62.46)             159,001 (58.58)   
   \<2--3 times/mo                      608 (12.57)               38,628 (14.23)    
   ≥once/wk                             1,208 (24.97)             73,788 (27.19)    
  Exercise                                                                          \<0.001
   No                                   2,682 (55.38)             154,422 (56.21)   
   ≤4 times/wk                          1,511 (31.20)             93,662 (34.09)    
   ≥5 times/wk                          650 (13.42)               26,635 (9.70)     
  Diabetes mellitus, mg/dL                                                          \<0.001
   Glucose \<100                        2,750 (55.38)             188,299 (66.70)   
   100≤ glucose                         \<126 1,152 (23.20)       65,349 (23.15)    
   126≤ glucose                         280 (5.64)                12,431 (4.40)     
   Prior diagnosis (under medication)   784 (15.79)               16,224 (5.75)     
  Hypertension                                                                      \<0.001
   No                                   874 (17.59)               76,378 (27.04)    
   Prehypertension                      1,459 (29.37)             103,312 (36.57)   
   Newly diagnosed                      1,055 (21.24)             54,568 (19.32)    
   Prior diagnosis (under medication)   1,580 (31.80)             48,232 (17.07)    
  Hypercholesterolemia, mg/dL                                                       \<0.001
   Total cholesterol \<200              2,274 (45.83)             146,157 (51.80)   
   2 00≤ total cholesterol \<240        1,469 (29.60)             86,871 (30.79)    
   240≤ total cholesterol               652 (13.14)               32,214 (11.42)    
   Prior diagnosis (under medication)   567 (11.43)               16,893 (5.99)     
  BMI level, kg/m^2^                                                                \<0.001
   \<18.5                               129 (2.60)                7,341 (2.60)      
   ≥18.5 and \<23                       1,694 (34.08)             103,958 (36.79)   
   ≥23 and \<25                         1,331 (26.78)             74,764 (26.46)    
   ≥25 and \<30                         1,624 (32.68)             87,769 (31.06)    
   ≥30                                  192 (3.86)                8,751 (3.10)      
  Income (low 20%)                      744 (14.97)               44,493 (15.75)    0.137
  Residential area (rural)              2,738 (55.09)             154,896 (54.81)   0.698

Values are presented as number (%) or mean±standard deviation. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### Association between metabolic parameters and the development of primary open-angle glaucoma

![](dmj-44-414-i002)

  Variable                               Cases   Person-years   Incidence rate^a^   HR     95% CI   
  -------------------------------------- ------- -------------- ------------------- ------ -------- ------
  Diabetes mellitus, mg/dL                                                                          
   FPG \<100                             2,750   2,258,482      1.22                1.00            
   100≤ FPG \<126                        1,152   784,899        1.47                1.21   1.13     1.29
   126≤ FPG                              280     149,754        1.87                1.54   1.36     1.74
   Under medication                      784     197,495        3.97                3.26   3.01     3.53
  Hypertension, mm Hg                                                                               
   SBP \<120 and DBP \<80                874     913,715        0.96                1.00            
   120≤ SBP \<140 or 80≤ DBP \<90        1,459   1,238,740      1.18                1.23   1.13     1.34
   SBP≥ 140 or DBP ≥90                   1,055   657,051        1.61                1.68   1.53     1.84
   Under medication                      1,580   583,359        2.71                2.83   2.61     3.08
  Hypercholesterolemia, mg/dL                                                                       
   TC \<200                              2,274   1,753,651      1.30                1.00            
   200≤ TC \<240                         1,469   1,043,186      1.41                1.09   1.02     1.16
   240≤ TC                               652     387,708        1.68                1.30   1.19     1.41
   Under medication                      567     204,060        2.78                2.14   1.95     2.35
  No. of metabolic syndrome components                                                              
   0                                     1,678   1,760,393      0.95                1.00            
   1                                     1,957   1,161,052      1.69                1.77   1.66     1.89
   2                                     1,044   399,266        2.61                2.74   2.54     2.96
   3                                     291     73,280         3.97                4.17   3.68     4.72
  Body mass index, kg/m^2^                                                                          
   \<18.5                                129     88,260         1.46                1.08   0.90     1.29
   18.5--22.9                            1,694   1,247,517      1.36                1.00            
   23--24.9                              1,331   898,068        1.48                1.09   1.02     1.17
   25--29.9                              1,624   1,054,854      1.54                1.13   1.06     1.21
   ≥30                                   192     105,294        1.82                1.35   1.16     1.56

HR, hazard ratio; CI, confidence interval; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol.

^a^Per 1,000 person-years.

###### Association between metabolic parameters and the development of primary open-angle glaucoma stratified by age (\<65 years vs. ≥65 years)

![](dmj-44-414-i003)

  Variable                               Age \<65 yr   Age ≥65 yr                                                                                        
  -------------------------------------- ------------- -------------- ------ ------ ------ ------ ------ ----- ------------ ------ ------- ------ ------ ------
  Diabetes mellitus, mg/dL                                                                                                                               
   FPG \<100                             1,907         1,955,984.48   0.97   0      1.00                 843   302,497.28   2.79   0       1.00          
   100≤ FPG \<126                        735           647,346.94     1.14   0.16   1.16   1.07   1.27   417   137,551.86   3.03   0.24    1.09   0.97   1.22
   126≤ FPG                              189           114,941.77     1.64   0.67   1.69   1.45   1.96   91    34,812.26    2.61   -0.18   0.94   0.76   1.16
   Under medication                      450           130,380.30     3.45   2.48   3.54   3.19   3.92   334   67,114.41    4.98   2.19    1.79   1.57   2.03
  Hypertension, mm Hg                                                                                                                                    
   SBP \<120 and DBP \<80                690           846,318.26     0.82   0      1.00                 184   67,397.16    2.73   0       1.00          
   120≤ SBP \<140 or 80≤ DBP \<90        1,077         1,096,390.73   0.98   0.17   1.20   1.10   1.33   382   142,349.41   2.68   -0.05   0.98   0.82   1.17
   SBP ≥140 or DBP ≥90                   706           531,937.65     1.33   0.51   1.63   1.47   1.81   349   125,112.96   2.79   0.06    1.02   0.85   1.22
   Under medication                      808           374,996.57     2.15   1.33   2.64   2.39   2.93   772   208,362.71   3.71   0.98    1.36   1.16   1.59
  Hypercholesterolemia, mg/dL                                                                                                                            
   TC \<200                              1,487         1,496,948.23   0.99   0      1.00                 787   256,702.38   3.07   0       1.00          
   200≤ TC \<240                         998           882,112.35     1.13   0.14   1.14   1.05   1.23   471   161,073.80   2.92   -0.14   0.95   0.85   1.07
   240≤ TC                               459           321,084.81     1.43   0.44   1.44   1.30   1.60   193   66,623.22    2.90   -0.17   0.94   0.81   1.11
   Under medication                      333           146,793.13     2.27   1.28   2.28   2.03   2.57   234   57,266.67    4.09   1.02    1.33   1.15   1.54
  No. of metabolic syndrome components                                                                                                                   
   0                                     1,298         1,607,533.71   0.81   0      1.00                 380   152,859.37   2.49   0       1.00          
   1                                     1,201         914,342.32     1.31   0.51   1.63   1.50   1.76   756   246,710.15   3.06   0.58    1.23   1.09   1.39
   2                                     608           280,427.23     2.17   1.36   2.69   2.44   2.96   436   118,839.25   3.67   1.18    1.48   1.29   1.69
   3                                     176           48,312.48      3.64   2.84   4.51   3.85   5.28   115   24,967.86    4.61   2.12    1.85   1.50   2.28
  Body mass index, kg/m^2^                                                                                                                               
   \<18.5                                52            58,991.43      0.88   0      0.83   0.63   1.10   77    29,268.22    2.63   0       0.93   0.73   1.17
   18.5--22.9                            1,105         1,040,345.90   1.06   0.18   1.00                 589   207,170.84   2.84   0.21    1.00          
   23--24.9                              864           767,382.23     1.13   0.24   1.06   0.97   1.16   467   130,685.91   3.57   0.94    1.26   1.11   1.42
   25--29.9                              1,129         895,954.30     1.26   0.38   1.19   1.09   1.29   495   158,899.31   3.12   0.48    1.10   0.97   1.24
   ≥30                                   133           87,941.88      1.51   0.63   1.43   1.19   1.71   59    17,352.34    3.40   0.77    1.20   0.92   1.57

HR, hazard ratio; CI, confidence interval; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol.

^a^Per 1,000 person-years.

###### Association between metabolic parameters and the development of primary open-angle glaucoma stratified by gender

![](dmj-44-414-i004)

  Variable                               Male    Female                                                                                 
  -------------------------------------- ------- -------------- ------ ------ ------ ------ ------- -------------- ------ ------ ------ ------
  Diabetes mellitus, mg/dL                                                                                                              
   FPG \<100                             1,388   1,030,419.59   1.35   1.00                 1,362   1,228,062.17   1.11   1.00          
   100≤ FPG \<126                        637     435,454.94     1.46   1.09   0.99   1.19   515     349,443.86     1.47   1.33   1.20   1.47
   126≤ FPG                              176     95,980.30      1.83   1.36   1.16   1.59   104     53,773.73      1.93   1.74   1.43   2.13
   Under medication                      401     102,692.55     3.90   2.90   2.59   3.24   383     94,802.17      4.04   3.64   3.25   4.08
  Hypertension, mm Hg                                                                                                                   
   SBP \<120 and DBP \<80                431     348,980.35     1.24   1.00                 443     564,735.07     0.78   1.00          
   120≤ SBP \<140 or 80≤ DBP \<90        813     656,666.94     1.24   1.00   0.89   1.13   646     582,073.20     1.11   1.41   1.25   1.60
   SBP ≥140 or DBP ≥90                   632     396,399.11     1.59   1.29   1.14   1.46   423     260,651.50     1.62   2.07   1.81   2.36
   Under medication                      726     263,175.99     2.76   2.23   1.98   2.52   854     320,183.28     2.67   3.40   3.03   3.81
  Hypercholesterolemia, mg/dL                                                                                                           
   TC \<200                              1,324   882,106.59     1.50   1.00                 950     871,544.01     1.09   1.00          
   200≤ TC \<240                         750     514,691.57     1.46   0.97   0.89   1.06   719     528,494.58     1.36   1.25   1.13   1.38
   240≤ TC                               295     180,000.50     1.64   1.09   0.96   1.24   357     207,707.53     1.72   1.58   1.40   1.78
   Under medication                      231     86,719.55      2.66   1.77   1.54   2.04   336     117,340.24     2.86   2.63   2.32   2.97
  No. of metabolic syndrome components                                                                                                  
   0                                     918     811,328.32     1.13   1.00                 760     949,064.76     0.80   1.00          
   1                                     1,048   618,877.73     1.69   1.50   1.37   1.64   909     542,174.75     1.68   2.09   1.90   2.31
   2                                     498     200,703.01     2.48   2.19   1.97   2.45   546     198,563.47     2.75   3.43   3.08   3.83
   3                                     139     34,894.75      3.98   3.52   2.95   4.21   152     38,385.59      3.96   4.94   4.15   5.89
  Body mass index, kg/m^2^                                                                                                              
   \<18.5                                63      41,854.18      1.51   0.98   0.76   1.26   66      46,405.48      1.42   1.18   0.92   1.52
   18.5--22.9                            866     560,994.84     1.54   1.00                 828     686,521.91     1.21   1.00          
   23--24.9                              729     461,221.30     1.58   1.02   0.93   1.13   602     436,846.84     1.38   1.14   1.03   1.27
   25--29.9                              877     560,424.31     1.56   1.01   0.92   1.11   747     494,429.30     1.51   1.25   1.13   1.38
   ≥30                                   68      41,309.18      1.65   1.07   0.84   1.37   124     63,985.04      1.94   1.61   1.33   1.94

HR, hazard ratio; CI, confidence interval; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol.

^a^Per 1,000 person-years.

###### Association between metabolic status and incident primary open-angle glaucoma

![](dmj-44-414-i005)

         Cases   Person-years   Incidence rate^a^   Model 1                Model 2                Model 3
  ------ ------- -------------- ------------------- ---------------------- ---------------------- ----------------------
  MHNO   1,233   1,306,444      0.94                1                      1                      1
  MUNO   1,921   927,400        2.07                2.191 (2.040--2.354)   1.515 (1.406--1.632)   1.521 (1.405--1.645)
  MHO    445     453,949        0.98                1.038 (0.931--1.157)   1.052 (0.944--1.173)   1.019 (0.907--1.144)
  MUO    1,371   706,199        1.94                2.056 (1.903--2.220)   1.575 (1.457--1.703)   1.574 (1.449--1.711)

Values are presented as hazard ratio (95% confidence interval). Model 1: unadjusted; Model 2: adjusted for age, gender; Model 3: adjusted for age, gender, smoking, alcohol, exercise, income, and residential area.

MHNO, metabolically healthy nonobese; MUNO, metabolically unhealthy nonobese; MHO, metabolically health obese; MUO, metabolically unhealthy obese.

^a^Per 1,000 person-years.
